Suzhou-based immuno-oncology specialist CStone raised a $260m Series B round and Brii launched with $260m in Series A cash to develop drugs for the China market. Also, multiple start-ups launched recently with more than $50m in Series A rounds, including Ansun, Beam, Casma, Celsius and Neurana.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in May.
Ansun BioPharma Inc., which is developing antiviral biologics for respiratory tract infections, raised $85m in a Series A financing...
The biotech had been looking at options to survive since May.
Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
Deal Snapshot: The biotech will receive up to $750m from Gilead for molecular glue degraders against CDK2.
Lilly-rejected candidate impresses in Phase IIb atopic dermatitis trial.
